Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Principal Component Analysis of the Cytokine and Chemokine Response to Human Traumatic Brain Injury

  • Adel Helmy ,

    adelhelmy@cantab.net

    Affiliation Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom

  • Chrystalina A. Antoniades,

    Affiliation Nuffield Department of Clinical Neurosciences, Department of Clinical Neurology, John Radcliffe Hospital, University of Oxford, United Kingdom

  • Mathew R. Guilfoyle,

    Affiliation Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom

  • Keri L. H. Carpenter,

    Affiliations Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom, Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom

  • Peter J. Hutchinson

    Affiliations Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom, Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom

Principal Component Analysis of the Cytokine and Chemokine Response to Human Traumatic Brain Injury

  • Adel Helmy, 
  • Chrystalina A. Antoniades, 
  • Mathew R. Guilfoyle, 
  • Keri L. H. Carpenter, 
  • Peter J. Hutchinson
PLOS
x

Abstract

There is a growing realisation that neuro-inflammation plays a fundamental role in the pathology of Traumatic Brain Injury (TBI). This has led to the search for biomarkers that reflect these underlying inflammatory processes using techniques such as cerebral microdialysis. The interpretation of such biomarker data has been limited by the statistical methods used. When analysing data of this sort the multiple putative interactions between mediators need to be considered as well as the timing of production and high degree of statistical co-variance in levels of these mediators. Here we present a cytokine and chemokine dataset from human brain following human traumatic brain injury and use principal component analysis and partial least squares discriminant analysis to demonstrate the pattern of production following TBI, distinct phases of the humoral inflammatory response and the differing patterns of response in brain and in peripheral blood. This technique has the added advantage of making no assumptions about the Relative Recovery (RR) of microdialysis derived parameters. Taken together these techniques can be used in complex microdialysis datasets to summarise the data succinctly and generate hypotheses for future study.

Introduction

Traumatic Brain Injury (TBI) is a multifaceted pathology including diverse mechanisms such as excitotoxicity, free radical formation, disrupted metabolism and brain swelling [1]. A range of cytokines and chemokines have been implicated in these pathophysiological consequences of TBI [2], [3]. Cytokines are paracrine and autocrine mediators of inflammation produced by a number of central nervous system cell types, including neurones, astrocytes and microglia and can be measured in a range of biological fluids including blood, cerebrospinal fluid and microdialysate [4]. Disentangling the roles and inter-relationships between these mediators is a key goal in developing a mechanistic understanding of neuronal loss following TBI as well as identifying novel therapeutic targets [5]. However, there are a number of practical difficulties in interpreting human cytokine data due to the large number of inter-related variables, variations in monitoring period in relation to time of injury and missing data points [6]. Many authors have attempted to use univariate correlations between a given mediator and a clinical outcome to draw inferences regarding the biological action of a cytokine, often pigeon-holing a cytokine as ‘beneficial’ or ‘damaging’ [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18]. This approach may be flawed for several reasons both in this context and within the wider TBI biomarker literature. Firstly, as there is a common trigger to cytokine production, namely TBI, the change in concentration of these mediators will likely correlate with each other and with the severity of injury irrespective of their ultimate biological action. Secondly, it is clear that cytokines that are directly antagonistic to one another at the same receptor (such as IL1β and IL1ra) are both produced in response to TBI in concert and may therefore correlate positively with each other [19]. Thirdly, the actions of a given cytokine are dependent on the time period and context in which it is produced [3], [20]. There is therefore a need for multivariate statistical techniques that incorporate the putative statistical interactions between cytokines in order to interpret and analyse cytokine data of this type. Multivariate regression is a ubiquitous technique within the biological literature, however it is limited by the need for large numbers of subjects in relation to the number of variables measured to prevent overfitting. In addition, without interpolation techniques, multivariate regression cannot compensate for missing data points potentially requiring observations to be discarded from the model. In contrast, multivariate projection methods such as principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA) and their various derivatives provide a powerful method for exploring complex datasets with multiple variables and missing data points with relatively small numbers of observations [21], [22], [23].

We have previously described the measurement of 42 cytokines in brain extracellular fluid in 12 patients with severe TBI for 5 days at 6 hourly time points as well as in concurrent blood samples [6]. We demonstrated a stereotyped sequence of cytokine production within the brain following injury as well as significantly higher concentrations of some cytokines in brain compared with blood. We have investigated this dataset using multivariate projection methods in order to explore the underlying structure within the cerebral cytokine response. Firstly, we have sought to identify the clusters of cytokines that discriminate between patients as a focus for future studies into neuroinflammation following TBI. Secondly, we have explored the change in this pattern over time. Thirdly, we have sought to identify the differences between the innate inflammatory response within brain extracellular space compared with that in peripheral blood following trauma.

Materials and Methods

In total, twelve patients with diffuse severe traumatic brain injury defined as a post-resuscitation Glasgow Coma Score≤8, a consistent mechanism of injury and consistent neuroimaging were monitored with cerebral microdialysis, arterial and jugular venous plasma sampling for a total of five days.

Ethics Statement

The study protocol was reviewed and approved by the Cambridgeshire Local Research Ethics Committee (2). Written informed assent was taken from the next of kin of all patients in line with our locally agreed protocols with Cambridgeshire Local Research Ethics Committee (2).

Microdialysis

CMA71(CMA Microdialysis AB, Solna, Sweden) high molecular weight cut-off microdialysis catheters (nominal cut-off 100 kDa) were perfused with 3.5% Human Albumin Solution made up in CMA CNS perfusion fluid) (Pharmacy Manufacturing Unit, Ipswich Hospital NHS Trust, UK), at a rate of 0.3 µl/minute, using CMA 106 (CMA Microdialysis AB, Solna, Sweden) microinfusion pumps. Samples were pooled in six hour time epochs before analysis. All catheters were placed through cranial access devices (Technicam, Newton Abbot, UK), into areas of brain that were consistent with diffuse injury on neuroimaging. At timepoints during which microdialysis was stopped for clinical indications (e.g. during MR imaging), these timepoints were noted as ‘missing’.

thumbnail
Table 2. Number of Principal Components Derived and Proportion of Variation Explained.

https://doi.org/10.1371/journal.pone.0039677.t002

Plasma Sampling

Whole blood samples were taken from each patient twice daily into EDTA vials from an arterial line in the radial artery. Samples were centrifuged at 5000 rpm at 4°C for 15 minutes and the resulting supernatant aliquoted and stored at −80°C until assayed. The timing of plasma samples was also related to the time of injury as for microdialysate.

Cytokine Analysis

The samples were analysed in duplicate using the Milliplex™ Multi-Analyte Profiling Human Cytokine/Chemokine 42 analyte premixed kit (Millipore Corp, Missouri, USA) on the Luminex 200 system (Luminex Corporation, Austin, TX, USA) running STarstation software(Applied Cytometry Systems, Sheffield, UK). Table 1 lists the cytokines and chemokines assayed. Cytokine standards were run on each plate and used to determine an eight-point five-parameter logistic standard curve. Plasma and micodialysate samples were assayed on separate plates with appropriate standards and background wells.

thumbnail
Figure 1. 48 Hour Time Pools Principal Component Analysis.

The figure shows cerebral microdialysis derived cytokine data from 12 patients (A–L) pooled into 48 hour time epochs(1–4). Principal component analysis has been used to identify the first 2 principal components which explain 63.7% of the variation in the dataset. Part A is a scores plot which shows the scores on each principal component for each of the observations. Part B is a loading plot which shows the cytokines which load on the respective principal components. Functionally related cytokines, such as IL1b and TNF, cluster within the same quadrant of the plot suggesting that they co-vary.

https://doi.org/10.1371/journal.pone.0039677.g001

thumbnail
Figure 2. 48 Hour Time Pools Partial Least Squares Discriminant Analysis.

The figure shows the same cerebral microdialysis derived cytokine data as in figure 1, from 12 patients (A–L) pooled into 48 hour time epochs (Red 0–48 hours, Green 48–96 hours, Blue 96–144 hours, Yellow 144–192 hours). Partial Least Squares Discriminant Analysis is a regression extension of Principal Component Analysis in which the model identifies the greatest sources of variation between pre-specified groups of observations. In this case the supervising variable is time. There is a clear shift in the pattern of observations in the scores plot (part A) over time from the 0–48 hour epoch (red) to the 48–96 hour time epoch (green) to the later time points (blue and yellow). The loading plot (part B) illustrates the cytokines that are responsible for the pattern apparent in part a.

https://doi.org/10.1371/journal.pone.0039677.g002

thumbnail
Figure 3. 72 Hour Time Pools Principal Component Analysis.

The figure shows cerebral microdialysis derived cytokine data from 12 patients (A–L) pooled into 72 hour time epochs(1,2). Principal component analysis has been used to identify the first 2 principal components which explain 55.6% of the variation in the dataset. Part A is a scores plot which shows the scores on each principal component for each of the observations. Part B is a loading plot which shows the cytokines which load on the respective principal components. In a similar pattern to figure 1, IL1b and TNF still cluster within the same quadrant of the plot.

https://doi.org/10.1371/journal.pone.0039677.g003

thumbnail
Figure 4. 72 Hour Time Pools Partial Least Squares Discriminant Analysis.

The figure shows the same cerebral microdialysis derived cytokine data as in figure 3, from 12 patients (A–L) pooled into 72 hour time epochs (Red 0–72 hours, Green 72–144 hours). Partial Least Squares Discriminant Analysis is a regression extension of Principal Component Analysis in which the model identifies the greatest sources of variation between pre-specified groups of observations. In this case the supervising variable is time. There is a clear shift in the pattern of observations in the scores plot (part A) over time from the early time points (red) to the later time points (green). The loading plot (part B) illustrates the cytokines that are responsible for the pattern apparent in part a.

https://doi.org/10.1371/journal.pone.0039677.g004

thumbnail
Figure 5. Paired Microdialysis and Plasma Samples Principal Component Analysis.

The figure shows paired microdialysate and plasma derived cytokine data from 12 patients. Principal component analysis has been used to identify the first 2 principal components which explain 33.4% of the variation within the dataset. Part A is a scores plot which shows the scores for each observation on each of the principal components and even in this unsupervised model a clear separation between microdialysis and plasma derived cytokines is apparent. Part B is a loading plot which shows the cytokines responsible for the differences between the two biological compartments.

https://doi.org/10.1371/journal.pone.0039677.g005

thumbnail
Figure 6. Paired Microdialysis and Plasma Samples Partial Least Squares Discriminant Analysis.

This figure shows paired microdialysate and plasma derived cytokine data from 12 patients as in figure 5. In this instance the source of the sample (microdialysate vs plasma) has been used as a supervising variable within a partial least squares discriminant analysis to identify two principal components that maximise the differentiation between the two biological compartments. Part A is a scores plot which shows the scores on each principal component for each observation. As with figure 5, there is a clear separation between the two biological compartments. Part B is a loading plot which demonstrates which cytokines are responsible for the difference apparent in part a. The cytokines on the left side of the figure show a comparative neural tropism when the two biological compartments are compared.

https://doi.org/10.1371/journal.pone.0039677.g006

Multivariate Statistical Analysis

Statistical analysis was performed using multivariate techniques, specifically principal component analysis (PCA), followed by partial least squares discriminant analysis (PLS – DA). SIMCA – P+ version 12 (Umetrics, Umea, Sweden) was used to identify principal components which accounted for the majority of the variation within the dataset. PCA is an unsupervised method and a data reduction technique that allows the major sources of variation in a multi-dimensional dataset to be analysed without introducing inherent bias. PLS – DA is a regression extension of the principal component analysis that uses class information to maximize the separation between various groups of observations. To estimate the number of PCA and PLS-DA components, cross-validation was used [21]. Data for each cytokine was mean centred and variance scaled to unit variance. SIMCA-P+ uses NIPALS (non-linear iterative partial least squares) algorithm to calculate the first few principal components and inherently compensates for missing data values. This has been suggested as a more accurate, though computationally more complex method for deriving eigenvalues [24]. Cross validation was carried out by dividing the data into seven parts and comparing models with each of the seven parts left in or out in turn. Predicted Residual Sum of Squares are calculated for the whole dataset and scaled to provide the Q2 statistic.

Cerebral cytokine data was pooled into 48 hour and 72 hour bins, following the time of injury, in order to ease the interpretation of the numerous time points and minimise missing data values. The 48 hour bins are 1(0–48 hours), 2 (48–96 hours), 3 (96–144 hours), 4 (144–192 hours) and 72 hour bins are 1 (0–72 hours), 2 (72–144 hours. For transparency we have included the PCA and temporally defined PLS-DA analyses for both 48 hour and 72 hour time bins. The monitoring period for each patient in relation to injury varies, therefore data is not available for every patient for every time point.

The analysis was performed in two stages. Firstly a PCA analysis was performed to examine any intrinsic variation in the cytokine data set and whether any clustering was presented at this stage. Removal of outliers made no difference in the model and outliers are included in all models presented. Secondly, PLS – DA was performed using the cytokine data, to demonstrate the separation of the time points and also identify the cytokines responsible for any of the clustering/separation present.

Cerebral cytokine data was also compared to concurrent plasma samples using the both PCA and PLS-DA methodology. In this case, we have not sought to make a comparison across time, so individual observations (‘microdialysis’ vs ‘plasma’) have been entered into the model directly. In this case, our aim was to define a subset of neurotropic cytokines.

Results

Six models were derived in total: the number of principal components derived, and the variation explained by these components for each of the models is summarised in Table 2. R2 describes the goodness of fit fraction of the sum of squares of all the variables explained by a principal component and Q2 describes the goodness of prediction of the fraction of the total variation of the variables that can be predicted by a principal component using cross-validation methods.

Each of the figures 1, 2, 3, 4, 5, 6 relates to one of the six models in Table 2 and is made up of two parts which are closely related. Part ‘a’ of each figure shows the scores plot obtained using SIMCA-P+. The scores plot shows the scores for each observation on Principal Component (PC)1 and PC2. Strictly speaking the SIMCA algorithm provides an estimate of the PC, which is more correctly referred to on the figures as t [1]/t [2] on the scores plots and p [1]/p [2] on the loading plots. PC is used within the text for ease of reference although we accept that they are not identical to principal components. The ellipse on the plot (Hotelling ellipse) is the 95% confidence interval for the model, hence plots of this type are sometimes referred to as Hotelling plots. Part ‘b’ in each of the figures shows the corresponding loading plot. The loading plot illustrates the relative contribution of each of the cytokines (referred to as the ‘loading’) to the two principal components. It is a linear contribution of each of these loadings that determines the score for each observation in the scores plot.

The scores plot is used to determine if there is clustering of observations, which would suggest a common underlying multivariate signal (or in this case pattern of cytokines) exists for that particular cluster of observations. Observations on the scores plot that lie within the Hotelling ellipse are within the 95% confidence interval for the model and are therefore well modelled in statistical terms. In order to interpret the cytokines responsible for a given multivariate signal reference is made to the loading plot. Cytokines with a larger loading on a PC in a particular direction contribute more heavily to the multivariate signal in that direction and therefore make a greater contribution to observations with high scores on that PC. Moreover, cytokines which cluster on the loading plot have a high degree of co-variance when the sources of variation in the model are considered.

Principal Component Analysis and PLS – DA of Pooled Microdialysate Data

The 48 hour microdialysate pooled data for each patient is plotted individually in figure 1. The model generated four principle components that explain 63.7% of the variation within the dataset. The first two principal components are presented and together explain 44.5% of the variation within the dataset. All data points, other than E1 fall within the 0.95 Hotelling ellipse. The corresponding loading plot (Figure 1b) demonstrates distinct clusters of cytokines. PLS-DA of the same data using the time point as the supervising variable (Figure 2a) demonstrates that there is a consistent shift across time in the pattern of cytokine expression following TBI. The corresponding PLS-DA plot (Figure 2b) illustrates the cytokine loadings responsible for this shift. The same analysis was repeated on 72 hour time bins and is presented in figures 3 and 4. The same features are apparent within these models despite the difference in time epoch used. Namely, the observations fall within the Hotelling ellipse, distinct clusters of cytokines are apparent in the PCA loading plot (Figure 3b), PLS-DA demonstrates a clear separation of observations (Figure 4a) and the same cytokines are responsible for this multivariate signal on the PLS-DA loading plot (Figure 4b) as in the 48 hour time epoch (Figure 2b).

Comparison between Cerebral and Plasma Cytokine Profiles

We have also performed a PCA on the data set of paired blood and MD data to determine whether a multivariate signal was present. Figure 5 shows a PCA of this data demonstrating clear separation in cytokine profiles even within the unsupervised model. Figure 6 shows the corresponding PLS-DA data reinforcing the separation in cytokine profile between these two biological compartments. The cytokines appearing to the left of the PLS-DA scores plot (Figure 6b) are more negatively loaded on PC1 and seem to be responsible for the separation in patterns of response between brain extracellular space and plasma.

Discussion

Principal Component Analysis of Microdialysate Data

PCA is an unsupervised dimension reduction technique which generates latent variables designated prinicipal components. The first PC is a linear combination of each of the original variables which incorporates the greatest sources of variation within a dataset. The second and subsequent PCs are further latent variables that explain the greatest sources of variation that are left over beyond the first PC and lie orthogonal to it. In our initial analysis we have incorporated data from all 12 patients for a range of time-points pooled into 48 and 72 hour bins. Exploring the sources of variation within this dataset using PCA gives an indication of the cytokines responsible for variation between patients and over time, without making any assumptions about which patient or which time-point each observation has come from. Each observation is therefore made up of 42 individual cytokine concentrations from a given patient (A–L) at a given time-point (1–4 in the 48 hour pools and 1–2 in the 72 hour pools). Comparing the models generated using 48 hour and 72 hour time pools demonstrates clustering of the same groups of cytokines. This suggests that the models are robust and do not simply reflect idiosyncrasies of the time pools presented. The polarity of some of the PCs are inverted when figures 1 and 2 are compared with figures 3 and 4, however this does not change the interpretation of the plots and is a reflection of the algorithm used to generate the PC. Table 2 lists the amount of variation explained by each of the models demonstrating that for both the 48 hour and 72 hour pools ∼45% of the total variation in the dataset is explained by just the first two PC. Given the recognised heterogeneity in human TBI [25], this degree of dimension reduction whilst explaining a large degree of variation adds credence to the robustness of the models.

The loading plots (Figure 1b, Figure 3b) plot the relative contribution of each cytokine to the respective PC illustrated in in the scores plots. The loading plots allow us to explore the largest sources of variation within the dataset and identify clusters of cytokines that closely co-vary. The current literature on TBI and cytokines focuses on a relatively small group of mediators. The two cytokines most commonly implicated in a pro-inflammatory role are IL1β and TNF. These cytokines share intracellular transduction mechanisms [26] and have synergistic actions in cell culture models [27], [28]_ENREF_35. They appear in the same quadrant in both PCA loading plots (top right figure 1b, bottom right figure 3b) suggesting concomitant production. Conversely, IL1ra, an endogenous competitive antagonist to IL1β appears in the opposing quadrant of the loading plots (bottom right figure 1b, top right figure 3b). Interestingly, IL1α, another agonist at the IL-1 receptor appears immediately adjacent to IL1ra and therefore closely co-varies with IL1ra. This relationship has not previously been described in the literature. It is not possible to determine what the functional consequences of this relationship are simply based on the PCA model, however it may be that as IL1α is produced concurrently with IL1ra it may not act as effectively as an agonist at the IL1 receptor as IL1β. There is pre-clinical evidence demonstrating differential effects of IL1α and IL1β [29] as well as a more prominent role for IL1β in inducing neurodegeneration than for IL1α [30]. This potentially adds to the considerable complexity in the regulation of the IL1 receptor pathway [31] and may result in differences in the potencies of IL1α and IL1β action in vivo. Furthermore, it clearly illustrates how biological mediators with opposing functions can closely co-vary. There is no way to definitively infer what a PC represents biologically, however, on the basis of the location of TNF, IL1β and IL1ra and the prior evidence for the role of these cytokines following TBI, we would suggest that PC2 represents some aspect of the pro-inflammatory consequences of IL1β/TNF action in contrast to the cytokines loading negatively on this axis.

Several chemokines were recovered using microdialysis and the loading plot reveals that many of these are produced concomitantly. For example, MIP1α (CCL-3) and MIP1β (CCL-4) appear adjacent to each other and can both signal through the CCR5 receptor [32]. The functional consequences of this relationship are not known and have never been investigated directly in the context of neuro-inflammation. In this way the PCA model can generate hypotheses relating to specific mediators that are produced in concert in vivo.

The relationship between humoral and cellular inflammation has been explored extensively in the peripheral immune system. There is increasing interest in the role of microglia following TBI and their ability to carry out a functional switch between a pro-inflammatory and a reparative role. The nomenclature used by different authors varies, however IFNγ is thought to promote a pro-inflammatory phenotype (classical-activation/Th1 type response/M1 subtype) while IL-4 promotes an anti-inflammatory response (regulatory/Th2 type response/M2 subtype). IL4 and IFNγ, appear immediately adjacent to each other on the far right of the loading plot. Furthermore, both IL10 and IL12 have been implicated in phenotypic plasticity of macrophages and they also appear within in the same region of the loading plot [33], [34].

Partial Least Squares Discriminant Analysis Using Pooled Timepoints

As well as looking for sources of variation in the dataset as a whole, multivariate projection techniques can also look for sources of variation between pre-specified observations. These so-called supervised techniques include PLS-DA. In this case, we have chosen to define ‘time following injury’ as the supervising variable. This allows an identification of the underlying patterns of cytokine that are responsible for changes in time in this patient group. The degree of variation explained by the models necessarily drops to around 1/3 of the total variation (Table 2) as the PCs now maximise variation specifically within in the time domain.

Figure 2a demonstrates that there is separation of the time points on the scores plot with observations at the first time point clustering towards the top left quadrant and observations from the third time point clustering towards the lower right quadrant. Figure 4a shows even clearer separation of the two time points, although the polarity of the PC is inverted. This pattern is not replicated for every patient (e.g. patient K moves from top right quadrant towards the bottom left quadrant in figure 3a and from top right quadrant to bottom left quadrant in figure 4a) however the observations fall within the Hotelling 95% significance ellipse, again suggesting that the PLS-DA model is an accurate representation of the underlying dataset. It is not clear what is responsible for this difference but no inference can be made solely on the results from a single patient.

Inspection of the loading plots for the PLS-DA (figures 2b and 4b) reveal the cytokines that are responsible for the changing pattern of response over time. As the loading of a cytokine on a given PC is linearly related to the score that observation receives in the scores plot, we can infer that the cluster of cytokines in the quadrant of the loading plot adjacent to the first time point (e.g. IL6, GRO, G-CSF, IP10) are produced earlier following injury in relation to cytokines appearing in the opposite quadrant (e.g IL10, MCP3, IL17). These models therefore suggest that there are distinct temporal phases to the innate inflammatory response to brain trauma. An important caveat to the interpretation of the cytokines responsible for ‘early’ vs ‘late’ patterns, is that microdialysis monitoring in patients is not available immediately at the time of injury. In practice, a minimum of 24 hours elapses before a patient is resuscitated, transferred to neurocritical care and monitoring is instituted. For this reason, cytokines that are known to be produced and released within the first 24 hours following injury are likely to be under-represented within this model as their levels are already likely to have peaked and may have returned to baseline levels at the time of monitoring. We would therefore expect that cytokines that peak at 24–48 or 24–72 hours are most likely to load highly for the early time points. From an analysis of the time at which each cytokine has its highest (peak) value following TBI [6], this would appear to be the case for IL6, G-CSF and IP10. Similarly IL10 appears to have its highest values at day 5–6 and appears in the later time points. Both, IL10 and IL17 have both been implicated in the interaction between cells of the macrophage lineage and regulatory T-cell responses [33], [35]. This temporal shift may therefore represent a shift from innate to adaptive immunity in the cerebral cytokine profile following TBI.

Comparison between Microdialysate and Plasma Patterns of Cytokine Production

We have also explored the relationship between the systemic inflammatory response, as gauged within plasma, and the cerebral inflammatory response to trauma. In order to make this comparison we have used temporally paired serum and microdialysate samples assayed using the same technique for the same substances. Figure 5a shows the hotelling plot and loading plot for the entire dataset. It is immediately apparent that even in an unsupervised model, there is a clear separation between observations made in the two compartments. We have also carried out a PLS-DA on this dataset using the biological source of the sample (microdialysate vs plasma) as the supervising variable (Figure 6). The close concordance between the loading plots in the PCA and PLS-DA models suggests a robust differentiation between the two compartments.

The individual mediators involved in inflammation are ubiquitous and implicated in several contexts and pathologies. Identifying tissue specific variations provides an insight into the subtleties of the inflammatory response in TBI. Almost all the microdialysate observations load negatively on PC1 in contrast to the plasma samples (Figure 6). The cytokines loading most heavily in this direction are the chemokines MCP-1, MCP-3, MIP1α, MIP1β, IP-10 and the cytokines IL-6 and IL-8. Several recent studies have highlighted the importance of MCP-1 (CCL-2) in the pathogenesis of TBI in animal models [36], [37]. It has also been shown to modulate cytokine production in a mouse culture model [38]. This comparative neural tropism of this group of chemokines suggests that, in response to TBI, they are playing a more pronounced role centrally rather than systemically. This is not to say that the other mediators are unimportant in TBI, however the patterns of expression are more equally distributed between the central and peripheral compartments. The same caveats regarding monitoring period also apply in this context i.e. cytokines and chemokines that may show differences between the two biological compartments in the first 24 hours following injury will not be identified in this analysis.

Advantages of Multivariate Projection Methods

There is a growing recognition that humoral mediators of innate inflammation (i.e. cytokines and chemokines) play a mechanistic role in the pathophysiological processes in a range of neurological disorders including HIV encephalitis [39], ischaemic stroke [40] as well as in TBI [3]. Microdialysis is unique in its ability to sample the extracellular fraction of soluble mediators, providing a direct and temporally distinct proxy for the biology of the brain extracellular space [41]. However, biomarker studies of this type are intrinsically limited in their interpretation by the fact that each of the measured variables is likely to show multi-collinearity with other related variables. Studies which sample only a few or even single cytokines within a biological compartment and attempt a univariate correlation with clinical parameters or with other biomarkers may be confounded by a range of other factors such as severity of injury or other unmeasured biomarkers [5], [42]. This can lead to erroneous conclusions about the role of cytokines as beneficial or harmful based on these simplistic correlations. As our understanding of innate inflammation following TBI has developed, it has become apparent that a given cytokine may play a dual role, damaging or reparative, depending on the context in which it is expressed either in terms of timescale or the co-existent cytokine milieu [3], [5], [43], [44], [45]. The complexity and subtleties of these interactions are difficult to model mathematically, however, without taking these putative interactions into account an understanding of cytokine biology will continue to elude us. Multivariate regression has been used extensively in the TBI literature to relate a range of variables to clinical outcome following TBI including clinical parameters (such as age, GCS, pupillary function) [46], [47], [48], microdialysate parameters (L/P ratio) [49] and serum parameters (Hb, PT) [50]. This statistical method requires large numbers of observations as the number of variables increases and often take measures at single timepoints (e.g. admission serum parameters) [50] or take a mean of the measured variable (e.g. L/P ratio over monitoring period) [49] to reduce the number of variables incorporated to a manageable number [51]. This has the potential to discard potentially useful temporal information. Cytokine data, in particular, is characterised by marked rises in concentration that are short lived. If the concentration of a cytokine is averaged over the entire monitoring period (equivalent to the area under the time-concentration curve if sampling time points are evenly spaced), the mean may be heavily influenced by the length of the monitoring period at which baseline levels are measured [5].

In order to address some of these issues we have utilised well characterised multivariate projection techniques, one of a range of chemometric methods [52], to explore the sources of variation within a complex human cytokine dataset. The greatest advantage of the approach presented here is that no prior assumptions are made as to which cytokines or mediators are of ‘importance’. The option to carry out multiple t-tests comparing a subset cytokines which are already well characterised, as in several of the studies referenced above, incorporates inherent bias into any analysis and perpetuates this bias in the literature as a whole. While it is impossible to draw any direct inference with regards to the biological function of a given mediator based on the analyses presented here, this does not detract from the ability to generate hypotheses and identify previously unrecognised relationships. The same statistical methodology may have additional utility in the analysis of data from alternative analytical techniques in TBI such as proteomics [53].

Limitations

Microdialysis is intrinsically a focal monitor and the question arises as to whether the volume of brain sampled by the catheter is truly representative of the brain as a whole, particularly in view of the heterogeneity of TBI such that the volume sampled may be more or less injured compared with other brain areas. There is some evidence that the inflammatory response is distributed within both hemispheres, even in focal injuries [54], and patients within this study were prospectively selected on the basis of diffuse brain injuries. Another issue that has drawn attention within the microdialysis literature is that of relative recovery (RR), i.e. the proportion of a substance within the extracellular space that crosses the microdialysis membrane and can be recovered in the microdialysis fluid [55]. We have previously demonstrated that RR varies between cytokines depending on their physico-chemical properties such as pI and molecular weight [56]. For this reason the relative concentrations of mediators assayed within the microdialysis fluid may not reflect the absolute concentrations within the brain extracellular space. However, the multivariate projection methods employed compensate for both differences in RR and for variations in the underlying degree of injury sampled by the catheter, by normalising the data. In this way the model identifies patterns of response between mediators unrelated to the absolute concentration of any given mediator in any given catheter. This is one of the key advantages of these techniques in analysing microdialysis data. This normalisation also allows for a direct comparison in the patterns of expression between the responses in plasma and brain extracellular space irrespective of absolute values. While an estimate of RR is not required to carry out these analyses, comparisons between patients still require the RR to be consistent between catheters and patients. The factors affecting RR have been reviewed extensively in the literature [55], [56]. Mediators that have a high random variation in RR are less likely to be contribute to variation in supervised models, such as the PLS-DA, and will therefore have a diminished loading on a given PC.

A further criticism of microdialysis for assessing the inflammatory response to trauma is the suggestion that insertion of the catheter, in itself, triggers an injurious response that is superimposed on the response to the initial trauma. The existing cerebral microdialysis literature provides evidence against this [5]. Firstly, cytokines that are shown in animal models to be produced early (e.g. IL1β, TNF) following injury are not sampled in patients in which monitoring commences later following injury [6]. If the cytokine response was in response to catheter insertion, there would be a consistent temporal response irrespective of the time of catheter insertion to time of injury. Secondly, there are pathology specific differences in production of cytokines when conditions such as subarachnoid haemorrhage [57] and tumour [58] patients are compared with those following TBI [6]. Thirdly, there appears to be a stereotyped sequence of cytokine production when the time lag between the time of injury and the ‘peak’ cytokine concentration is observed [6]. This is reinforced in this study in Figures 2 and 4. The pattern of cytokine response is apparent despite the variation between patients in the time frame over which monitoring occurs. The clustering of time points occurs when the time following injury is used rather than time from monitoring. It can be seen in this figure that some patients did not have any samples in the first 48 hours, however their pattern of cytokine production remains consistent with patients that did have early monitoring. It should be pointed out that the issue of ‘trauma artefact’ is a contentious one in the microdialysis literature [59] and some authors have suggested discarding the initial samples (e.g. the first 24 hours [60]) following catheter insertion despite the points made above.

In the analysis of cerebral cytokines we have chosen to pool our data into 48 and 72 hour blocks. There is a balance to be struck between smoothing out random variations at a given time-point and maintaining an appropriate degree of temporal resolution. Taking a mean over a period of time also helps to minimise missing data points and adds a degree of clarity to the scores plots in figures 1, 2, 3, 4. We accept that this is entirely subjective and is in the authors’ opinion the time frame which provides the clearest representation of the data.

All the models presented are derived from the same cohort of 12 patients. There is a risk that the models presented are an idiosyncrasy of the particular dataset used to generate them. In statistical terms this is referred to as ‘over-fitting’. Cross-validation is used to provide an estimate of the predictive ability of the model however ultimately the most stringent test would be to collect data from a further cohort of patients and plot them on the same PCs to provide an empirical validation.

One issue that we have not been able to address is the reasons for any variation in cytokine pattern seen between patients. It would be tempting to pick out other clinical factors such as GCS or an outcome measure such as Glasgow Outcome Score (GOS) and attempt a PLS-DA. However, in a small cohort of patients such as this, we do not feel this would be scientifically justifiable. These analyses will require larger patient numbers in order to utilise multivariate techniques to analyse clinical parameters such as these. Ultimately, the most useful application of PLS-DA may be in interventional studies in which patient populations that are subjected to differing treatment paradigms can be compared in terms of their biological response. This may provide a more sensitive chemical surrogate for treatment efficacy than conventional outcome measures such as GOS.

Microdialysis has been evaluated extensively as a monitor for cerebral metabolism following TBI [49], [61] however our understanding of the biology of cytokines and chemokines in this context is not at a stage where we can promote its use as a clinical tool. Furthermore, the time and cost of recovering these samples, laboratory analysis and statistical testing does not lend itself to ‘on-line’ clinical decision making.

Conclusion

In this study we have utilised multivariate projection techniques to reveal how inflammatory mediators demonstrate a distinct pattern of response to TBI in humans. Firstly, we have shown that several mediators show close co-variance (e.g. IL1α and IL1ra) indicating that they are produced in concert as a result of injury. Secondly, we have identified cytokines and chemokines that are produced at defined time points (e.g. IL6 at 24–48 hours, IL-10 at 96–144 hours) and discriminate between different temporal phases of the inflammatory response. Lastly, we have demonstrated that there are tissue specific variations (brain vs blood) in the patterns of mediators that are produced as a result of TBI.

In an observational study such as this no inference can be made as to the specific functions attributable to a given cluster of mediators, however by empirically determining the patterns of response the interactions of specific mediators can be explored further in animal and cell culture models. In particular, these techniques compensate for the inherent difficulties related to analysing multiple closely related mediators related to multi-collinearity, missing data points, mediators produced at different absolute concentration ranges and data from small numbers of patients. We envisage that this method can be extended into randomised studies in which cytokine data can be compared between patients receiving specific interventions.

Acknowledgments

CAA has been trained in the use of SIMCA-P+ by Umetrics, AB however she derives no financial inducement from Umetrics, AB.

Author Contributions

Conceived and designed the experiments: AH PJH. Performed the experiments: AH. Analyzed the data: AH CAA MRG. Contributed reagents/materials/analysis tools: AH CAA MRG. Wrote the paper: AH. Reviewed manuscript: KLHC PJH. Provided statistical advice: CAA.

References

  1. 1. Andriessen TM, Jacobs B, Vos PE (2010) Clinical characteristics and pathophysiological mechanisms of focal and diffuse traumatic brain injury. J Cell Mol Med 14: 2381–2392.TM AndriessenB. JacobsPE Vos2010Clinical characteristics and pathophysiological mechanisms of focal and diffuse traumatic brain injury.J Cell Mol Med1423812392
  2. 2. Schmidt OI, Heyde CE, Ertel W, Stahel PF (2005) Closed head injury–an inflammatory disease? Brain Res Brain Res Rev 48: 388–399.OI SchmidtCE HeydeW. ErtelPF Stahel2005Closed head injury–an inflammatory disease?Brain Res Brain Res Rev48388399
  3. 3. Morganti-Kossmann MC, Satgunaseelan L, Bye N, Kossmann T (2007) Modulation of immune response by head injury. Injury 38: 1392–1400.MC Morganti-KossmannL. SatgunaseelanN. ByeT. Kossmann2007Modulation of immune response by head injury.Injury3813921400
  4. 4. Loane DJ, Byrnes KR (2010) Role of microglia in neurotrauma. Neurotherapeutics 7: 366–377.DJ LoaneKR Byrnes2010Role of microglia in neurotrauma.Neurotherapeutics7366377
  5. 5. Helmy A, Simoni MG, Guilfoyle MR, Carpenter KL, Hutchinson PJ (2011) Cytokines and innate inflammation in the pathogenesis of human traumatic brain injury. Prog Neurobiol. A. HelmyMG SimoniMR GuilfoyleKL CarpenterPJ Hutchinson2011Cytokines and innate inflammation in the pathogenesis of human traumatic brain injury.Prog Neurobiol
  6. 6. Helmy A, Carpenter KL, Menon DK, Pickard JD, Hutchinson PJ (2011) The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production. J Cereb Blood Flow Metab 31: 658–670.A. HelmyKL CarpenterDK MenonJD PickardPJ Hutchinson2011The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production.J Cereb Blood Flow Metab31658670
  7. 7. Stein DM, Kufera JA, Lindell A, Murdock KR, Menaker J, et al. (2011) Association of CSF biomarkers and secondary insults following severe traumatic brain injury. Neurocrit Care 14: 200–207.DM SteinJA KuferaA. LindellKR MurdockJ. Menaker2011Association of CSF biomarkers and secondary insults following severe traumatic brain injury.Neurocrit Care14200207
  8. 8. Stein DM, Lindell A, Murdock KR, Kufera JA, Menaker J, et al. (2011) Relationship of serum and cerebrospinal fluid biomarkers with intracranial hypertension and cerebral hypoperfusion after severe traumatic brain injury. J Trauma 70: 1096–1103.DM SteinA. LindellKR MurdockJA KuferaJ. Menaker2011Relationship of serum and cerebrospinal fluid biomarkers with intracranial hypertension and cerebral hypoperfusion after severe traumatic brain injury.J Trauma7010961103
  9. 9. Hergenroeder GW, Moore AN, McCoy JP Jr, Samsel L, Ward NH 3rd, et al (2010) Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury. J Neuroinflammation 7: 19.Hergenroeder GW, Moore AN, McCoy JP Jr, Samsel L, Ward NH 3rd, et al2010Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury.J Neuroinflammation719
  10. 10. Hayakata T, Shiozaki T, Tasaki O, Ikegawa H, Inoue Y, et al. (2004) Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock 22: 102–107.T. HayakataT. ShiozakiO. TasakiH. IkegawaY. Inoue2004Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury.Shock22102107
  11. 11. Shiozaki T, Hayakata T, Tasaki O, Hosotubo H, Fuijita K, et al. (2005) Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury. Shock 23: 406–410.T. ShiozakiT. HayakataO. TasakiH. HosotuboK. Fuijita2005Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury.Shock23406410
  12. 12. Kirchhoff C, Buhmann S, Bogner V, Stegmaier J, Leidel BA, et al. (2008) Cerebrospinal IL-10 concentration is elevated in non-survivors as compared to survivors after severe traumatic brain injury. Eur J Med Res 13: 464–468.C. KirchhoffS. BuhmannV. BognerJ. StegmaierBA Leidel2008Cerebrospinal IL-10 concentration is elevated in non-survivors as compared to survivors after severe traumatic brain injury.Eur J Med Res13464468
  13. 13. Pleines UE, Morganti-Kossmann MC, Rancan M, Joller H, Trentz O, et al. (2001) S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J Neurotrauma 18: 491–498.UE PleinesMC Morganti-KossmannM. RancanH. JollerO. Trentz2001S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury.J Neurotrauma18491498
  14. 14. Pleines UE, Stover JF, Kossmann T, Trentz O, Morganti-Kossmann MC (1998) Soluble ICAM-1 in CSF coincides with the extent of cerebral damage in patients with severe traumatic brain injury. J Neurotrauma 15: 399–409.UE PleinesJF StoverT. KossmannO. TrentzMC Morganti-Kossmann1998Soluble ICAM-1 in CSF coincides with the extent of cerebral damage in patients with severe traumatic brain injury.J Neurotrauma15399409
  15. 15. Singhal A, Baker AJ, Hare GM, Reinders FX, Schlichter LC, et al. (2002) Association between cerebrospinal fluid interleukin-6 concentrations and outcome after severe human traumatic brain injury. J Neurotrauma 19: 929–937.A. SinghalAJ BakerGM HareFX ReindersLC Schlichter2002Association between cerebrospinal fluid interleukin-6 concentrations and outcome after severe human traumatic brain injury.J Neurotrauma19929937
  16. 16. Chiaretti A, Antonelli A, Mastrangelo A, Pezzotti P, Tortorolo L, et al. (2008) Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury. J Neurotrauma 25: 225–234.A. ChiarettiA. AntonelliA. MastrangeloP. PezzottiL. Tortorolo2008Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury.J Neurotrauma25225234
  17. 17. Chiaretti A, Barone G, Riccardi R, Antonelli A, Pezzotti P, et al. (2009) NGF, DCX, and NSE upregulation correlates with severity and outcome of head trauma in children. Neurology 72: 609–616.A. ChiarettiG. BaroneR. RiccardiA. AntonelliP. Pezzotti2009NGF, DCX, and NSE upregulation correlates with severity and outcome of head trauma in children.Neurology72609616
  18. 18. Hillman J, Aneman O, Persson M, Andersson C, Dabrosin C, et al. (2007) Variations in the response of interleukins in neurosurgical intensive care patients monitored using intracerebral microdialysis. J Neurosurg 106: 820–825.J. HillmanO. AnemanM. PerssonC. AnderssonC. Dabrosin2007Variations in the response of interleukins in neurosurgical intensive care patients monitored using intracerebral microdialysis.J Neurosurg106820825
  19. 19. Hutchinson PJ, O’Connell MT, Rothwell NJ, Hopkins SJ, Nortje J, et al. (2007) Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-1beta, and their endogenous inhibitor IL-1ra. J Neurotrauma 24: 1545–1557.PJ HutchinsonMT O’ConnellNJ RothwellSJ HopkinsJ. Nortje2007Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-1beta, and their endogenous inhibitor IL-1ra.J Neurotrauma2415451557
  20. 20. Pinteaux E, Trotter P, Simi A (2009) Cell-specific and concentration-dependent actions of interleukin-1 in acute brain inflammation. Cytokine 45: 1–7.E. PinteauxP. TrotterA. Simi2009Cell-specific and concentration-dependent actions of interleukin-1 in acute brain inflammation.Cytokine4517
  21. 21. Eriksson L, Antti H, Gottfries J, Holmes E, Johansson E, et al. (2004) Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem 380: 419–429.L. ErikssonH. AnttiJ. GottfriesE. HolmesE. Johansson2004Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm).Anal Bioanal Chem380419429
  22. 22. Eriksson L JE, Kettaneh-Wold N, Wold S (2001) Multi- and megavariate data analysis–principles and applications. : Umetrics AB. JE Eriksson LN. Kettaneh-WoldS. Wold2001Multi- and megavariate data analysis–principles and applications.: Umetrics AB
  23. 23. Eriksson L, Johansson E, Kettaneh-Wold N, Trygg J, Wikstrom J, et al. (2006) Multi- and megavariate data analysis, Part II, Advanced applications and method extensions, second revised and enlarged edition. Umetrics AB. L. ErikssonE. JohanssonN. Kettaneh-WoldJ. TryggJ. Wikstrom2006Multi- and megavariate data analysis, Part II, Advanced applications and method extensions, second revised and enlarged edition.Umetrics AB
  24. 24. Boulesteix AL, Strimmer K (2007) Partial least squares: a versatile tool for the analysis of high-dimensional genomic data. Brief Bioinform 8: 32–44.AL BoulesteixK. Strimmer2007Partial least squares: a versatile tool for the analysis of high-dimensional genomic data.Brief Bioinform83244
  25. 25. Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, et al. (2008) Classification of traumatic brain injury for targeted therapies. J Neurotrauma 25: 719–738.KE SaatmanAC DuhaimeR. BullockAI MaasA. Valadka2008Classification of traumatic brain injury for targeted therapies.J Neurotrauma25719738
  26. 26. Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135–145.R. Medzhitov2001Toll-like receptors and innate immunity.Nat Rev Immunol1135145
  27. 27. Chao CC, Hu S, Ehrlich L, Peterson PK (1995) Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain Behav Immun 9: 355–365.CC ChaoS. HuL. EhrlichPK Peterson1995Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors.Brain Behav Immun9355365
  28. 28. Downen M, Amaral TD, Hua LL, Zhao ML, Lee SC (1999) Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia 28: 114–127.M. DownenTD AmaralLL HuaML ZhaoSC Lee1999Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha.Glia28114127
  29. 29. Andre R, Pinteaux E, Kimber I, Rothwell NJ (2005) Differential actions of IL-1 alpha and IL-1 beta in glial cells share common IL-1 signalling pathways. Neuroreport 16: 153–157.R. AndreE. PinteauxI. KimberNJ Rothwell2005Differential actions of IL-1 alpha and IL-1 beta in glial cells share common IL-1 signalling pathways.Neuroreport16153157
  30. 30. Patel HC, Bouamra O, Woodford M, King AT, Yates DW, et al. (2005) Trends in head injury outcome from 1989 to 2003 and the effect of neurosurgical care: an observational study. Lancet 366: 1538–1544.HC PatelO. BouamraM. WoodfordAT KingDW Yates2005Trends in head injury outcome from 1989 to 2003 and the effect of neurosurgical care: an observational study.Lancet36615381544
  31. 31. Simi A, Tsakiri N, Wang P, Rothwell NJ (2007) Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans 35: 1122–1126.A. SimiN. TsakiriP. WangNJ Rothwell2007Interleukin-1 and inflammatory neurodegeneration.Biochem Soc Trans3511221126
  32. 32. Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29: 313–326.SL DeshmaneS. KremlevS. AminiBE Sawaya2009Monocyte chemoattractant protein-1 (MCP-1): an overview.J Interferon Cytokine Res29313326
  33. 33. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958–969.DM MosserJP Edwards2008Exploring the full spectrum of macrophage activation.Nat Rev Immunol8958969
  34. 34. Murray PJ, Wynn TA (2011) Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol 89: 557–563.PJ MurrayTA Wynn2011Obstacles and opportunities for understanding macrophage polarization.J Leukoc Biol89557563
  35. 35. Dong C (2008) TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8: 337–348.C. Dong2008TH17 cells in development: an updated view of their molecular identity and genetic programming.Nat Rev Immunol8337348
  36. 36. Semple BD, Bye N, Ziebell JM, Morganti-Kossmann MC (2010) Deficiency of the chemokine receptor CXCR2 attenuates neutrophil infiltration and cortical damage following closed head injury. Neurobiol Dis 40: 394–403.BD SempleN. ByeJM ZiebellMC Morganti-Kossmann2010Deficiency of the chemokine receptor CXCR2 attenuates neutrophil infiltration and cortical damage following closed head injury.Neurobiol Dis40394403
  37. 37. Semple BD, Bye N, Rancan M, Ziebell JM, Morganti-Kossmann MC (2010) Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2−/− mice. J Cereb Blood Flow Metab 30: 769–782.BD SempleN. ByeM. RancanJM ZiebellMC Morganti-Kossmann2010Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2−/− mice.J Cereb Blood Flow Metab30769782
  38. 38. Semple BD, Frugier T, Morganti-Kossmann MC (2010) CCL2 modulates cytokine production in cultured mouse astrocytes. J Neuroinflammation 7: 67.BD SempleT. FrugierMC Morganti-Kossmann2010CCL2 modulates cytokine production in cultured mouse astrocytes.J Neuroinflammation767
  39. 39. Yao H, Bethel-Brown C, Li CZ, Buch SJ (2010) HIV neuropathogenesis: a tight rope walk of innate immunity. J Neuroimmune Pharmacol 5: 489–495.H. YaoC. Bethel-BrownCZ LiSJ Buch2010HIV neuropathogenesis: a tight rope walk of innate immunity.J Neuroimmune Pharmacol5489495
  40. 40. Ceulemans AG, Zgavc T, Kooijman R, Hachimi-Idrissi S, Sarre S, et al. (2010) The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia. J Neuroinflammation 7: 74.AG CeulemansT. ZgavcR. KooijmanS. Hachimi-IdrissiS. Sarre2010The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia.J Neuroinflammation774
  41. 41. Helmy A, Carpenter KL, Hutchinson PJ (2007) Microdialysis in the human brain and its potential role in the development and clinical assessment of drugs. Curr Med Chem 14: 1525–1537.A. HelmyKL CarpenterPJ Hutchinson2007Microdialysis in the human brain and its potential role in the development and clinical assessment of drugs.Curr Med Chem1415251537
  42. 42. Helmy A, Timofeev I, Palmer CR, Gore A, Menon DK, et al. (2010) Hierarchical log linear analysis of admission blood parameters and clinical outcome following traumatic brain injury. Acta Neurochir (Wien) 152: 953–957.A. HelmyI. TimofeevCR PalmerA. GoreDK Menon2010Hierarchical log linear analysis of admission blood parameters and clinical outcome following traumatic brain injury.Acta Neurochir (Wien)152953957
  43. 43. Shohami E, Ginis I, Hallenbeck JM (1999) Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev 10: 119–130.E. ShohamiI. GinisJM Hallenbeck1999Dual role of tumor necrosis factor alpha in brain injury.Cytokine Growth Factor Rev10119130
  44. 44. Popovich PG, Longbrake EE (2008) Can the immune system be harnessed to repair the CNS? Nat Rev Neurosci 9: 481–493.PG PopovichEE Longbrake2008Can the immune system be harnessed to repair the CNS?Nat Rev Neurosci9481493
  45. 45. Swartz KR, Liu F, Sewell D, Schochet T, Campbell I, et al. (2001) Interleukin-6 promotes post-traumatic healing in the central nervous system. Brain Res 896: 86–95.KR SwartzF. LiuD. SewellT. SchochetI. Campbell2001Interleukin-6 promotes post-traumatic healing in the central nervous system.Brain Res8968695
  46. 46. Marmarou A, Lu J, Butcher I, McHugh GS, Murray GD, et al. (2007) Prognostic value of the Glasgow Coma Scale and pupil reactivity in traumatic brain injury assessed pre-hospital and on enrollment: an IMPACT analysis. J Neurotrauma 24: 270–280.A. MarmarouJ. LuI. ButcherGS McHughGD Murray2007Prognostic value of the Glasgow Coma Scale and pupil reactivity in traumatic brain injury assessed pre-hospital and on enrollment: an IMPACT analysis.J Neurotrauma24270280
  47. 47. Mushkudiani NA, Engel DC, Steyerberg EW, Butcher I, Lu J, et al. (2007) Prognostic value of demographic characteristics in traumatic brain injury: results from the IMPACT study. J Neurotrauma 24: 259–269.NA MushkudianiDC EngelEW SteyerbergI. ButcherJ. Lu2007Prognostic value of demographic characteristics in traumatic brain injury: results from the IMPACT study.J Neurotrauma24259269
  48. 48. Murray GD, Butcher I, McHugh GS, Lu J, Mushkudiani NA, et al. (2007) Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. J Neurotrauma 24: 329–337.GD MurrayI. ButcherGS McHughJ. LuNA Mushkudiani2007Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study.J Neurotrauma24329337
  49. 49. Timofeev I, Carpenter KL, Nortje J, Al-Rawi PG, O’Connell MT, et al. (2011) Cerebral extracellular chemistry and outcome following traumatic brain injury: a microdialysis study of 223 patients. Brain 134: 484–494.I. TimofeevKL CarpenterJ. NortjePG Al-RawiMT O’Connell2011Cerebral extracellular chemistry and outcome following traumatic brain injury: a microdialysis study of 223 patients.Brain134484494
  50. 50. Van Beek JG, Mushkudiani NA, Steyerberg EW, Butcher I, McHugh GS, et al. (2007) Prognostic value of admission laboratory parameters in traumatic brain injury: results from the IMPACT study. J Neurotrauma 24: 315–328.JG Van BeekNA MushkudianiEW SteyerbergI. ButcherGS McHugh2007Prognostic value of admission laboratory parameters in traumatic brain injury: results from the IMPACT study.J Neurotrauma24315328
  51. 51. Ramon J, Fierens D, Guiza F, Meyfroidt G, Blockeel H, et al. (2007) Mining data from intensive care patients. Advanced Engineering Informatics 21: 243–256.J. RamonD. FierensF. GuizaG. MeyfroidtH. Blockeel2007Mining data from intensive care patients.Advanced Engineering Informatics21243256
  52. 52. Gasteiger J (2006) Chemoinformatics: a new field with a long tradition. Anal Bioanal Chem 384: 57–64.J. Gasteiger2006Chemoinformatics: a new field with a long tradition.Anal Bioanal Chem3845764
  53. 53. Hanrieder J, Wetterhall M, Enblad P, Hillered L, Bergquist J (2009) Temporally resolved differential proteomic analysis of human ventricular CSF for monitoring traumatic brain injury biomarker candidates. J Neurosci Methods 177: 469–478.J. HanriederM. WetterhallP. EnbladL. HilleredJ. Bergquist2009Temporally resolved differential proteomic analysis of human ventricular CSF for monitoring traumatic brain injury biomarker candidates.J Neurosci Methods177469478
  54. 54. Frugier T, Morganti-Kossmann MC, O’Reilly D, McLean CA (2010) In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury. J Neurotrauma 27: 497–507.T. FrugierMC Morganti-KossmannD. O’ReillyCA McLean2010In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury.J Neurotrauma27497507
  55. 55. Dahlin AP, Wetterhall M, Caldwell KD, Larsson A, Bergquist J, et al. (2010) Methodological aspects on microdialysis protein sampling and quantification in biological fluids: an in vitro study on human ventricular CSF. Anal Chem 82: 4376–4385.AP DahlinM. WetterhallKD CaldwellA. LarssonJ. Bergquist2010Methodological aspects on microdialysis protein sampling and quantification in biological fluids: an in vitro study on human ventricular CSF.Anal Chem8243764385
  56. 56. Helmy A, Carpenter KL, Skepper JN, Kirkpatrick PJ, Pickard JD, et al. (2009) Microdialysis of cytokines: methodological considerations, scanning electron microscopy, and determination of relative recovery. J Neurotrauma 26: 549–561.A. HelmyKL CarpenterJN SkepperPJ KirkpatrickJD Pickard2009Microdialysis of cytokines: methodological considerations, scanning electron microscopy, and determination of relative recovery.J Neurotrauma26549561
  57. 57. Mellergard P, Aneman O, Sjogren F, Saberg C, Hillman J (2011) Differences in cerebral extracellular response of interleukin-1beta, interleukin-6, and interleukin-10 after subarachnoid hemorrhage or severe head trauma in humans. Neurosurgery 68: 12–19; discussion 19. P. MellergardO. AnemanF. SjogrenC. SabergJ. Hillman2011Differences in cerebral extracellular response of interleukin-1beta, interleukin-6, and interleukin-10 after subarachnoid hemorrhage or severe head trauma in humans.Neurosurgery 68: 12–19; discussion 19
  58. 58. Marcus HJ, Carpenter KL, Price SJ, Hutchinson PJ (2010) In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol 97: 11–23.HJ MarcusKL CarpenterSJ PricePJ Hutchinson2010In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines.J Neurooncol971123
  59. 59. Stenken JA, Church MK, Gill CA, Clough GF (2010) How minimally invasive is microdialysis sampling? A cautionary note for cytokine collection in human skin and other clinical studies. AAPS J 12: 73–78.JA StenkenMK ChurchCA GillGF Clough2010How minimally invasive is microdialysis sampling? A cautionary note for cytokine collection in human skin and other clinical studies.AAPS J127378
  60. 60. Mellergard P, Aneman O, Sjogren F, Pettersson P, Hillman J (2008) Changes in extracellular concentrations of some cytokines, chemokines, and neurotrophic factors after insertion of intracerebral microdialysis catheters in neurosurgical patients. Neurosurgery 62: 151–157; discussion 157–158. P. MellergardO. AnemanF. SjogrenP. PetterssonJ. Hillman2008Changes in extracellular concentrations of some cytokines, chemokines, and neurotrophic factors after insertion of intracerebral microdialysis catheters in neurosurgical patients.Neurosurgery 62: 151–157; discussion 157–158
  61. 61. Bellander BM, Cantais E, Enblad P, Hutchinson P, Nordstrom CH, et al. (2004) Consensus meeting on microdialysis in neurointensive care. Intensive Care Med 30: 2166–2169.BM BellanderE. CantaisP. EnbladP. HutchinsonCH Nordstrom2004Consensus meeting on microdialysis in neurointensive care.Intensive Care Med3021662169